cells, the proportion of CD4+, CD8+and Treg subsets and the level of IFNγ production was heterogeneous between tumor samples (Fig.4a). Treatment with MCLA-145 increased IFNγ production in all tumor samples relative to control antibody and, to a lesser extent, comparator antibodies. This ...
a syngeneic mouse model as monotherapy as it enhances efficacy in combination with anti-PD-1, and the effect is dependent on the systemic availability of CD8+T cells. Thus, VSIG4 represents a promising new target capable of triggering an anti-cancer response via multiple key immune mechanisms....